Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
3.060
+0.210 (7.37%)
Jan 22, 2026, 1:05 PM EST - Market open
Serina Therapeutics Employees
As of December 31, 2024, Serina Therapeutics had 13 total employees, including 12 full-time and 1 part-time employees. The number of employees increased by 2 or 18.18% compared to the previous year.
Employees
13
Change (1Y)
2
Growth (1Y)
18.18%
Revenue / Employee
$8,923
Profits / Employee
-$1,446,385
Market Cap
32.63M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 13 | 2 | 18.18% | 12 | 1 |
| Dec 31, 2023 | 11 | - | - | 9 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SER News
- 6 days ago - Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity - GlobeNewsWire
- 5 weeks ago - Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry - GlobeNewsWire
- 6 weeks ago - Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program - GlobeNewsWire
- 2 months ago - Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewsWire
- 2 months ago - Serina Therapeutics Provides Regulatory Update on SER-252 Program - GlobeNewsWire
- 3 months ago - Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors - GlobeNewsWire
- 3 months ago - Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease - GlobeNewsWire
- 4 months ago - Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease - GlobeNewsWire